NCT00919919View on ClinicalTrials.gov

Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen

PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

November 30, 2010

Conditions
Endometrial HyperplasiaEndometrial Cancer
Interventions
DRUG

progesterone

Daily use of 100 mg progesterone vaginal tablet, and Estrofem; estradiol 1 mg administrated orally. for 6 month

DRUG

activella

Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally

Trial Locations (1)

Unknown

Rabin Medical Center Beilinson Hospital, Petah Tikva

Sponsors

Collaborators (1)

Ferring Pharmaceuticals
All Listed Sponsors
collaborator

Ferring Pharmaceuticals

INDUSTRY

lead

Rabin Medical Center

OTHER